Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ACE-Inhibitors and Angiotensin Receptor Blockers Clear all
Recruiting Phase 2 Interventional

A Study of Blood Pressure Control During Cancer Treatment

NCT06023576
View directory record Official record
Conditions
Breast Cancer, Cardiotoxicity
Interventions
antihypertensive medications, Blood pressure measurement, Echocardiogram, Symptom-limited cardiopulmonary exercise test, Quality of Life Measures, Biomarkers
Other · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 24, 2026, 10:44 AM EDT
Active, not recruiting No phase listed Observational

Rubix LS Diabetic Kidney Disease (DKD) Registry Study

NCT07348718
View directory record Official record
Conditions
Diabetic Kidney Disease (DKD)
Interventions
Kidney-Protective Therapies Used in Routine Care
Drug
Lead sponsor
Rubix LS
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 24, 2026, 10:44 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy

NCT00754143
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Nephropathy
Interventions
FG-3019
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Sep 24, 2026, 10:44 AM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 24, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study A

NCT00283686
View directory record Official record
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo, Standard Blood Pressure Control, Low Blood Pressure Control
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 24, 2026, 10:44 AM EDT
Completed No phase listed Observational

A Retrospective Analysis of the Use of ACE-inhibitors and Angiotensin Receptor Blockers

NCT00321945
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
ACE-Inhibitors and Angiotensin Receptor Blockers
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Sep 24, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Sep 24, 2026, 10:44 AM EDT
Terminated Not applicable Interventional

ACEI/ARB Study in Ambulatory and Day of Surgery Admission Patients

NCT03121092
View directory record Official record
Conditions
Hypertension, Hypotension
Interventions
ACEI or ARB
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 24, 2026, 10:44 AM EDT
Recruiting Phase 4 Interventional

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

NCT06218199
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Furosemide, Torsemide, Bumetanide, sacubitril/valsartan, Hydralazine, Isosorbide Dinitrate
Drug
Lead sponsor
Heart Center Research, LLC
Network
Eligibility
19 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 28, 2024 · Synced Sep 24, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

NCT01195662
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo matching Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 89 Years
Enrollment
2,245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 117 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 24, 2026, 10:44 AM EDT
Completed Not applicable Interventional

RAAS Optimization for Acute CHF Patients

NCT03695120
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Change of treatment plan
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 24, 2026, 10:44 AM EDT
Completed Phase 4 Interventional

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

NCT00185120
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Hydroclorothiazide, Benazepril, Amlodipine
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
20
States / cities
Mobile, Alabama • Long Beach, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Sep 24, 2026, 10:44 AM EDT
Completed Not applicable Interventional

Virtual Hypertension Clinic

NCT01167920
View directory record Official record
Conditions
Hypertension
Interventions
Virtual Hypertension Clinic
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 24, 2026, 10:44 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease

NCT01101269
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ACEI or ARB, Lisinopril
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 24, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis

NCT00732069
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Complication of Hemodialysis
Interventions
Placebo, Ramipril, Valsartan
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 24, 2026, 10:44 AM EDT
Recruiting Phase 4 Interventional

The STOP-MED CTRCD Trial

NCT06183437
View directory record Official record
Conditions
Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
Interventions
Stopping Heart Failure Medication(s)
Other
Lead sponsor
Dinesh Thavendiranathan
Other
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 24, 2026, 10:44 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035
View directory record Official record
Conditions
Chronic Kidney Disease, Proteinuria
Interventions
Finerenone (Kerendia, BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 17 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Palo Alto, California • San Diego, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 24, 2026, 10:44 AM EDT
Completed Not applicable Interventional Results available

Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019

NCT04338009
View directory record Official record
Conditions
COVID-19
Interventions
Discontinuation of ARB/ACEI, Continuation of ARB/ACEI
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Sep 24, 2026, 10:44 AM EDT
Active, not recruiting Phase 4 Interventional

Liraglutide Effect in Atrial Fibrillation

NCT03856632
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Liraglutide, RFM, Anti Arrhythmics, Afib Catheter Ablation
Drug · Other · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 24, 2026, 10:44 AM EDT
Completed No phase listed Observational

A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

NCT05096143
View directory record Official record
Conditions
Heart Failure
Interventions
Sacubitril/valsartan, ACEi/ARB
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
42,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Sep 24, 2026, 10:44 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

NCT01487109
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
CTP-499, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
49
States / cities
Tempe, Arizona • Harrisburg, Arkansas • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Sep 24, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study B

NCT01885559
View directory record Official record
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Sep 24, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

NCT02816736
View directory record Official record
Conditions
Heart Failure
Interventions
LCZ696, valsartan, LCZ696 placebo, valsartan placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Beverly Hills, California • Sacramento, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 24, 2026, 10:44 AM EDT
Terminated Phase 2 Interventional

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

NCT00913393
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
FG-3019, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Buena Park, California • Lakewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Sep 24, 2026, 10:44 AM EDT